Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of novel medicines and medical products based on dendrimer polymers, with programs targeting respiratory viruses, DEP® drug delivery, and VivaGel®. Starpharma has developed VIRALEZE™, an antiviral nasal spray registered for sale in Europe, Vietnam, India, New Zealand, and Saudi Arabia, and available in certain online markets outside Australia. Starpharma has three core development programs: the VivaGel® portfolio, DEP™ drug delivery, and agrochemicals, with multiple products being developed internally and through commercial collaborations.